GlassScriptPhysician profile
Umaree Bybee
NPI 1154788263
$4,626.47
in general payments reported to CMS, 2019-2025
16 companies · $613 in 2025
The $613 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $305 · 2023: $2,352 · 2024: $1,356 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,682 · Travel and Lodging: $639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,682.09 |
| Travel and Lodging | $639.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,451.22 | 2022-2025 | Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $975.05 | 2023-2024 | Farxiga, Lokelma, Brilinta |
| Abbott Laboratories | $370.82 | 2023-2025 | Triclip, Jot Dx, Cardiomems |
| Novo Nordisk INC | $365.90 | 2024-2025 | Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $354.28 | 2022-2024 | Verquvo |
| Impulse Dynamics (USA) INC. | $176.88 | 2024 | Optimizer |
| Amgen INC. | $153.19 | 2023-2024 | Repatha |
| Daiichi Sankyo INC. | $125.00 | 2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $121.17 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.43 | 2023-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.36 | 2023 | Jardiance |
| Scpharmaceuticals INC. | $108.53 | 2023 | |
| Novartis Pharmaceuticals Corporation | $81.38 | 2022-2023 | |
| Cvrx, INC. | $72.29 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $27.30 | 2024 | Xarelto |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $14.67 | 2024 | Vibativ |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umaree Bybee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.